Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natamycin + Lactulose in Vulvovaginal Candidiasis
NCT06411314Phase 3Completed
- Sponsor
- AVVA RUS JSC
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of natamycin and lactulose in vulvovaginal candidiasis (VVC) (3 arms), sponsored by AVVA RUS JSC. Primary endpoint: Proportion of patients who achieved a clinical response (recovery) at 7 days. Started Dec 2022; status: completed.
02
Drugs
natamycinlactulose
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT06411314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411314.